uthr stock — United Therapeutics Overview

uthr stock refers to United Therapeutics Corporation (Nasdaq: UTHR). This guide explains the ticker, company profile, market data, pipeline catalysts, risks, governance, and where to track official...

2024-07-11 02:43:00

By Crypto Trailblazer

Article rating

4.5

115 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

United Therapeutics Corporation (UTHR)

uthr stock refers to United Therapeutics Corporation, traded under the ticker symbol UTHR on the Nasdaq. This article explains what the uthr stock represents, where it trades, key company facts, typical market data, clinical and commercial drivers, governance and ownership, trading characteristics, risks, and reliable resources for live quotes and SEC filings. Readers will learn how product pipeline events and regulatory outcomes commonly influence uthr stock price moves and where to follow verified updates (Investor Relations, SEC EDGAR, and major market-data providers). Explore further on Bitget for trading and portfolio tracking.

Ticker and Exchange Details

Ticker symbol: UTHR (common stock)
Primary exchange: Nasdaq (United States)
Trading currency: USD
Typical U.S. market hours: 09:30–16:00 Eastern Time (regular session)
Sector / industry classification: Biotechnology / Specialty Pharmaceuticals
Identifiers: ISIN and CUSIP are published in official filings and market-data pages (check Nasdaq or company investor relations for the exact ISIN/CUSIP as of the latest filing).

Note: uthr stock is a U.S.-listed equity. When checking live trading or placing orders, Bitget is recommended as the platform highlighted in this guide for execution and portfolio services.

Company Overview

United Therapeutics Corporation is a biotech company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious conditions. Key points about the company:

Headquarters: United States (company site lists the official address and contact details).
Founded: United Therapeutics was incorporated to research and commercialize treatments for rare and life‑threatening conditions; check company history on the official investor relations page for founding year and milestones.
Leadership: The company’s executive team and board composition are detailed in its proxy statements and investor materials; notable long-standing executives have driven strategy in commercial and clinical development.
Major marketed products: The company’s commercial portfolio has included inhaled, infused, and oral therapies for PAH and other indications. Historically cited marketed products include remodulin (treprostinil infusion), tyvaso (inhaled treprostinil), orenitram (oral treprostinil), adcirca (tadalafil for PAH), and oncology asset unituxin (used in specific cancer indications). These product names have been important revenue drivers and clinical focus areas for uthr stock performance.
Core therapeutic focus: pulmonary arterial hypertension, with development programs exploring new delivery methods, extended indications, and related vascular or rare-disease therapies.

Stock Price and Market Data

Readers should verify live pricing on market-data platforms. For context and historical reference, major market-data providers maintain up-to-date dashboards for uthr stock (Yahoo Finance, MarketWatch, Robinhood, CNBC, Morningstar, Nasdaq). Example metrics commonly tracked for UTHR include:

Price (last trade / close): consult real-time quote providers for the current figure.
Market capitalization: displayed on quote pages; reflects shares outstanding × price.
52‑week high / 52‑week low: shown on data pages and useful for volatility context.
Volume and average daily volume: intraday trading activity and typical liquidity measures.
Beta: a volatility measure relative to the market.
Valuation metrics: trailing P/E, forward P/E (when applicable), EPS (TTM), P/S and other ratios available on major data sites.

As of June 30, 2024, according to Yahoo Finance and MarketWatch, typical publicly reported UTHR metrics included quoted price ranges, market capitalization and 52‑week ranges on the provider pages; readers should consult those pages for the exact and latest quantitative figures. (Note: numbers change daily; verify live quotes before making any decisions.)

Sources for live metrics: Yahoo Finance, MarketWatch, Robinhood, CNBC, Morningstar, Nasdaq.

Historical Price Performance

Multi-year trend: uthr stock has reflected a mix of drug-approval news, clinical-readout reactions, and broader biotech-market cycles. Over multi-year horizons, biotech equities like UTHR can show pronounced rallies tied to positive regulatory or clinical events and sharp drawdowns in risk-off markets.
Major milestones: product approvals, label expansions, patent outcomes, and earnings surprises have historically produced sizeable single-day or multi-week moves for the stock.
Corporate actions affecting price history: stock splits, reverse splits, large secondary offerings, or buybacks (if executed) would be disclosed in SEC filings and investor presentations. Check the company’s historical SEC filings for any structural changes that affect share counts or adjusted historical prices.

Financials and Valuation Metrics

Revenue and profitability: United Therapeutics’ revenue mix typically reflects product sales across its marketed portfolio and possible licensing or collaboration revenue. Net income or loss, profit margins, and cash position are detailed in quarterly (10-Q) and annual (10-K) reports.
Key valuation metrics: analysts and data providers report trailing and forward P/E, price-to-sales (P/S), and price-to-cash-flow (P/CF). Morningstar and Yahoo Finance commonly publish consensus valuation snapshots and analyst commentary for UTHR.
Fair value commentary: Morningstar often publishes a fair value estimate and stewardship rating for covered equities; check Morningstar for its latest UTHR valuation view.

As of June 30, 2024, Morningstar and other providers published valuation context on UTHR that incorporated recent revenue trends, product sales, and pipeline probability assumptions — consult those providers for the numeric estimates that are updated periodically.

Products, Pipeline and Clinical Catalysts

Commercial products: United Therapeutics’ marketed therapies for pulmonary hypertension and other indications form the core revenue base. Specific product performance, label changes, and distribution arrangements are reported in earnings releases.
Pipeline programs: biotech investors monitor Phase 2 and Phase 3 programs, potential new indications, and formulation or delivery innovations (e.g., oral vs inhaled delivery). Positive pivotal results or regulatory filings can materially affect uthr stock.
Upcoming catalysts: typical catalysts that move the stock include pivotal trial readouts, FDA/EMA advisory committee decisions, label expansions, or pivotal data readouts. Company press releases and clinicaltrials.gov list trial statuses and expected timelines.

Example: A pivotal Phase 3 readout or an FDA regulatory filing for a major program would be characterized across company releases and covered by CNBC, MarketWatch, and other outlets — and would commonly be highlighted in the “Recent News and Notable Events” section below when it occurs.

Corporate Actions, Governance and Insider Activity

Share repurchases and capital allocation: United Therapeutics’ board decisions on buybacks, dividends (if any), or capital raises are disclosed in investor presentations and SEC filings. Such actions influence uthr stock supply dynamics.
Board and executive changes: new appointments, departures, or compensation program changes appear in proxy statements (DEF 14A) and press releases.
Insider transactions: material insider buying or selling is reported in Forms 4 and summarized on market-data sites and SEC search tools; patterns of insider buying can be an informational data point for market participants but do not guarantee future performance.

Analyst Coverage and Market Sentiment

Consensus ratings: major houses and aggregated-data providers publish a distribution of analyst ratings (buy/hold/sell) and median price targets. Markets Insider, Yahoo Finance and CNBC often collate these consensus data points for UTHR.
Notable analyst actions: upgrades, downgrades or significant price-target revisions following earnings, trial readouts, or patent rulings frequently make headlines and influence short-term sentiment.

When tracking analyst sentiment for uthr stock, view the full research notes (where available) for the rationale behind changes rather than just the headline rating.

Trading Characteristics and Derivatives

Shares outstanding and float: total shares outstanding and public float are reported in the company’s filings and displayed by major data providers. These figures inform market-cap calculations and liquidity.
Average daily volume: a key liquidity measure; higher volume generally supports tighter spreads and easier execution.
Short interest: the percent of float sold short and days-to-cover are tracked by exchanges and data providers; elevated short interest can increase volatility around news events.
Options market liquidity: for many biotech equities, options are available and can be used by investors for hedging or directional strategies. Liquidity, common strikes and expirations vary with market interest — check options chains on market-data platforms for current open interest and implied volatility.

Legal, Patent and Competitive Issues

Patent litigation and IP risk: biotech companies often face patent disputes over key drugs. Patent expiration dates, pending litigation, or court rulings affecting exclusivity can materially change revenue forecasts and thus uthr stock valuation.
Competitive landscape: competing therapies, biosimilars, or new entrants can pressure pricing and market share for United Therapeutics’ products. Monitor competitor development and launch timelines.
Regulatory risk: adverse regulatory findings, recalls, or safety communications can directly reduce sales and negatively affect the stock.

Any material litigation or patent outcome is disclosed in SEC filings and covered by news outlets such as MarketWatch, CNBC, and Nasdaq news pages.

Risks and Investment Considerations

This section outlines common risk factors associated with uthr stock. These are general and based on typical biotech-company risk profiles; consult the company’s 10-K and 10-Q for the official, company‑stated risk factors.

Clinical risk: trial failures or unfavorable safety findings can erase anticipated future revenue and harm the stock.
Regulatory risk: delays or rejections by the FDA/EMA/other regulators impact commercial timing and expectations.
Product concentration: reliance on a small number of products for a large share of revenue increases sensitivity to competition and reimbursement shifts.
Pricing and reimbursement: changes in payer policies, government pricing rules, or reimbursement levels can compress revenues.
Patent and IP outcomes: loss of exclusivity or adverse patent rulings can accelerate generic or biosimilar competition.
Market volatility: biotech stocks are often more volatile than broader indexes, amplifying both gains and losses on uthr stock.

This guide does not provide investment advice. All decisions should be made after consulting primary filings and, if appropriate, a licensed financial professional.

Earnings and Financial Reporting

Earnings cadence: United Therapeutics typically reports quarterly results (Q1, Q2, Q3, Q4) and files an annual 10‑K; confirm the company’s investor relations page for the exact fiscal calendar and upcoming release dates.
Guidance practices: the company may provide revenue or EPS guidance in earnings releases or conference calls; analysts incorporate guidance into forward models.
SEC filings: 10‑Q, 10‑K, 8‑K (for material events), and proxy statements are authoritative sources for financial and governance information.

Resources to find filings: SEC EDGAR search (company filings) and the company’s investor relations web pages.

Ownership and Institutional Holders

Major institutional shareholders: institutional ownership percentages and top holders are displayed on many market-data pages and in company filings. Large institutional holders can influence liquidity and trading patterns.
Insider ownership: executive and director holdings are reported in proxy statements and Form 4 filings. Trends in insider purchases or sales are publicly disclosed.
Activist investors: any activist campaigns or formal proposals are typically disclosed in SEC filings and reported by financial news outlets.

Related Securities and Comparables

Investors and analysts often benchmark UTHR against peers in pulmonary arterial hypertension and broader specialty biotech. Typical comparable metrics include revenue growth, margin profiles, and R&D spend as percent of sales.

Peers commonly considered in comparative analysis include other specialty pharmaceutical and biotech companies developing cardiopulmonary or rare-disease therapies. When performing comparables, use consistent valuation multiples (EV/Revenue, P/E where applicable) and adjust for pipeline risk and product concentration.

Investor Resources

To follow uthr stock with primary, authoritative data, use the following resources (no external links are provided here):

United Therapeutics — official investor relations and press-release pages (company website)
SEC EDGAR — for 10‑K, 10‑Q, 8‑K, proxy filings and insider transaction forms
Real-time quote and metrics: Nasdaq quote page, Yahoo Finance, MarketWatch, Robinhood (quote & key stats), CNBC market profile, Morningstar valuations
Clinical trial status: clinicaltrials.gov and company pipeline pages for trial phases and enrollment status

For trading and portfolio tracking, Bitget is recommended in this guide as the platform to execute orders and monitor holdings.

References

Yahoo Finance — UTHR quote and company profile (market data and key stats). As of June 30, 2024, market-data pages included up-to-date pricing, market cap and volume metrics.
Robinhood — UTHR quote and key statistics (retail-oriented quote page and basic metrics).
MarketWatch — UTHR price, news summaries and analysis snippets.
CNN Markets / CNN Business — UTHR stock quote and insights.
Morningstar — UTHR valuation, fair value commentary and historical financials.
CNBC — UTHR profile, earnings coverage and financial reporting summaries.
Markets Insider / Business Insider — price tables and analyst consensus summaries.
Nasdaq — official listing information and market-data details.

All references above are primary market-data and news providers; verify the most recent numeric figures on the cited provider pages and the company’s SEC filings for authoritative numbers.

External Links (where to find more)

United Therapeutics investor relations (official site)
SEC EDGAR filings for United Therapeutics
Real-time market quotes: Nasdaq, Yahoo Finance (search UTHR on those pages)

Further exploration: to track live quotes, analyst research, and up-to-the-minute regulatory or clinical announcements that often drive uthr stock price movements, consult the listed market-data providers and company releases.

If you want, I can: provide a dated summary with specific numeric metrics (market cap, last close, 52-week range, average volume) pulled from a selected source and timestamped; or generate a concise watchlist of pipeline events and expected announcement dates relevant to uthr stock. To view or trade UTHR positions, explore Bitget’s portfolio tools and market interface for order execution and alerts.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.